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Abstract
The optimal treatment sequence for metastatic castration-resistant prostate cancer (mCRPC) is undetermined.
Retrospective assessment of 350 patients with mCRPC receiving different sequences of cabazitaxel (C) or
abiraterone acetate (A), or both, after docetaxel (D) treatment suggested that receipt of all 3 agents was
associated with improved overall survival (OS) versus the use of 2 agents (P[ .0002) in a multivariable analysis.
OS was increased with DCA versus DAC (P [ .0210).
Background: Optimal sequencing of cabazitaxel (C) and abiraterone acetate (A) after docetaxel (D) for metastatic
castration-resistant prostate cancer (mCRPC) is unclear. We assessed treatment patterns and outcomes in patients
with mCRPC receiving different sequences of A or C, or both, after administration of D. Methods: Retrospective
analysis was conducted of US Oncology Network iKnowMed (iKM) electronic health record (EHR) data to assess
patients with mCRPC who received treatment with D and were subsequently treated with C or A, or both, between
April 2011 and May 2012. Patients received 2 or 3 drugs: DA, DC, DAC, or DCA. Overall survival (OS) and time to
treatment failure (TTF) were analyzed by the Kaplan-Meier method from the start to the end of second-line therapy
after administration of D (TTF1) and to the end of combined second- and third-line therapy (TTF2) for 3-drug se-
quences. Multivariable Cox proportional hazard models evaluated the impact of baseline clinical prognostic factors
and treatment sequence on OS and TTF. Results: Of 350 patients who were treated with D and subsequent therapies,
183 (52.3%) received DA, 54 (15.4%) received DC, 77 (22.0%) received DCA, and 36 (10.3%) received DAC. In a
multivariable analysis, adjusted comparisons suggested that 3-drug sequences were associated with improved OS
versus 2-drug sequences (hazard ratio [HR], 0.21; 95% conﬁdence interval [CI], 0.092-0.476; P ¼ .0002). There were
no statistically signiﬁcant differences in OS and TTF for DC versus DA, and OS was signiﬁcantly greater for DCA
versus DAC (HR, 0.13; 95% CI, 0.022-0.733; P ¼ .0210). More cycles of C were administered in DCA than in DAC
(median 6 vs. 4; t test P < .0001), whereas the duration of A treatment was similar. Conclusion: Administration of 3
agents in the DCA sequence was more optimal for treating mCRPC in this hypothesis-generating study.
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310 -Introduction
First-line chemotherapy for metastatic castration-resistant pros-
tate cancer (mCRPC) with docetaxel (D) every 3 weeks plus
prednisone yields a median overall survival (OS) of nearly 19
months.1-3 Recent approval of many new promising treatments for
prostate cancer has led to a marked expansion of the therapeutic
arsenal in this clinical setting. Cabazitaxel (C), abiraterone acetate
(A), and enzalutamide improve OS when administered after treat-
ment with D.4-6 Treatment with A and enzalutamide have also
extended survival in chemotherapy-naive patients.7,8 Moreover,
sipuleucel-T prolonged survival in minimally symptomatic patients
and radium-223 prolonged survival in patients after administration
of D or in chemotherapy-ineligible patients with symptomatic bone
metastases.9,10 Further complicating decisions around sequencing of
agents in the metastatic prostate cancer setting is the release of
interim data from the National Cancer Instituteesponsored Eastern
Cooperative Oncology Group 3805 (ChemoHormonal Therapy
Versus Androgen Ablation Randomized Trial for Extensive Disease
in Prostate Cancer [CHAARTED]) study, which revealed an OS
advantage in patients with hormone-sensitive prostate cancer and
extensive metastatic disease who received D plus androgen-
deprivation therapy (ADT) versus ADT alone.11
Given the rapid proliferation of systemic therapies for mCRPC,
optimal sequencing after administration of D is an importantFigure 1 Consort Diagram
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Abbreviations: A ¼ abiraterone acetate; C ¼ cabazitaxel; CSA ¼ Comprehensive Strategic Alliance; D
acetate and then cabazitaxel; DC ¼ docetaxel followed by cabazitaxel; DCA ¼ docetaxel followed by
castration-resistant prostate cancer.
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OS remains unknown. Prospective trials comparing all possible se-
quences of agents are unlikely to be conducted. McKesson Specialty
Health’s iKnowMed (iKM) electronic health record (EHR) system
offers an opportunity to analyze and compare outcomes for different
sequences of therapy and may offer useful insights and generate
hypotheses when controlling for other known clinicopathologic
prognostic factors.
The ﬁrst objective of the current retrospective study was to
characterize patients receiving different sequences of C and A after
D, and the second objective was to estimate and compare clinical
outcomes in patients receiving these different sequences of therapy.
At the time this study was conceived, only C and A were approved
for the treatment of mCRPC after administration of D. We eval-
uated treatment patterns, OS, and time to treatment failure (TTF)
among patients with mCRPC receiving A or C, or both, after
administration of D and report the inﬂuence of number of lines of
therapy after treatment with D and the potential effect of speciﬁc
prognostic factors on outcomes.
Patients and Methods
Study Design and Patient Population
This study consisted of 350 men with mCRPC who had received
D and were subsequently administered C or A, or both, from Aprilts treated at 
s from CSA 
abilities
t 2 visits
atients
 treated during 
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types were not to be mutually 
exclusive. There were 14 
common patients)
  237 patients received D 
followed by either C or A in
          second-line
¼ docetaxel; DA ¼ docetaxel followed by abiraterone; DAC ¼ docetaxel followed by abiraterone
cabazitaxel and then abiraterone acetate; EHR ¼ electronic health record; mCRPC ¼ metastatic
Guru Sonpavde et al2011 (when both C and A were commercially available in the
United States) to May 2012. For inclusion in this study, patients
within the McKesson Specialty Health/US Oncology Network
database were required to have had at least 2 visits within the US
Oncology Network and to have received care at a Comprehensive
Strategic Alliance practice using the full EHR capacities of the iKM
database. Patients were excluded if they were enrolled in a clinical
trial or diagnosed with other tumors during the index period.
Data Sources
Data were primarily abstracted from McKesson Specialty
Health’s iKM EHR, which receives input from more than 1000
medical oncologists from 350 oncology centers in 19 US states. This
database includes more than 850,000 patients (12% of the US
cancer population). The data obtained consisted of demographics
and clinical, laboratory, and treatment data. Chart review was
conducted by clinical staff, which included nurses and pharmacists,
to supplement data captured by programmatic queries of the iKM
EHR. Documented vital status identiﬁed in iKM was supplemented
with date of death data from the Social Security Death Master File.
The patients’ Social Security numbers were used for data linkage
between iKM and the Social Security Death Master File.
Statistical Analysis
OS was measured from the date of initiation of second-line
therapy after administration of D to date of death, censoring pa-
tients who were still alive at last contact. TTF was assessed in 2
ways: TTF1 was the time from initiation to the end of second-line
treatment or death, whichever came ﬁrst, and TTF2 was the time
from the initiation of second-line treatment to the end of third-line
treatment or death, whichever came ﬁrst. Descriptive statistics with
95% conﬁdence intervals (CIs) were used to describe patient
demographics and clinical characteristics and frequency counts
and percentages were used to evaluate the reasons for treatment
discontinuation. A Fisher test/c2 test for categorical data or aTable 1 Drug Exposure and Treatment Discontinuation Rates
Two-Drug Sequence
Total
(N [ 237)
DC
(n [ 54)
DA
(n [ 183)
Docetaxel cycles, n
Mean (SD) 7.72 (6.14) 7.44 (4.29) 7.80 (6.59)
Median 6 6.5 6
Range 1-45 2-19 1-45
95% CI 6.93-8.50 6.27-8.61 6.84-8.76
Cabazitaxel cycles, n
Mean (SD) e 5.98 (4.93) e
Median e 5 e
Range e 1-20 e
95% CI e 7.32-4.63 e
A discontinuation rates
within 3 mo, n (%)
e e 39 (21.3)
Abbreviations: CI ¼ conﬁdence interval; DA ¼ docetaxel followed by abiraterone acetate; DAC ¼
cabazitaxel; DCA ¼ docetaxel followed by cabazitaxel and then abiraterone acetate; SD ¼ standardt test/Kruskal-Wallis test for continuous variables was conducted to
determine statistically signiﬁcant differences in patient characteris-
tics by treatment group. Median time to OS and TTF end points
were analyzed by the Kaplan-Meier method. A multivariable Cox
proportional hazards model was used to examine OS and TTF end
points, adjusting for the effect of covariate prognostic factors, which
were selected based on accessibility of measurements and their
usefulness for clinical prognostication or subject stratiﬁcation, or
both, in clinical trials.12
The primary variable for comparison was drug treatment
sequence, speciﬁcally within the 2-drug cohort comparing DC
versus DA and in the 3-drug cohort comparing C followed by A
after D (DCA) versus A followed by C after D (DAC), and then
comparing results from the 2- versus 3-drug sequences. Covariates
analyzed for effects on OS and TTF included age (in years) at the
initiation of second-line therapy, the Prostate Cancer Clinical Trial
Working Group subtype based on location of metastasis (bone with
or without lymph node metastasis and visceral or other metastasis),
use of narcotics, duration of baseline D treatment, duration of
second-line therapy in the 3-drug cohort, Charlson comorbidity
index (CCI) score, interaction of treatment and time, Gleason score,
and baseline prostate-speciﬁc antigen (PSA), alkaline phosphatase,
hemoglobin (considered anemic if < 13 g/L), and lactate dehy-
drogenase levels.
Results
Baseline Demographic and Clinical Characteristics
After screening 28,333 individuals with prostate cancer in the US
Oncology Network EHR, 350 patients with mCRPC who received
treatment with D met study eligibility criteria; 113 of these patients
were treated with both C and A, and 237 patients were treated with
only 1 of these agents (Figure 1). Among patients using 3 lines of
therapy, 77 received DCA and 36 received DAC. Within the 2-drug
cohort, 183 patients received A after D (DA) and 54 received C
after D (DC). The median duration of D treatment (6 cycles) wasThree-Drug Sequence
P Value
Total
(N [ 113)
DCA
(n [ 77)
DAC
(n [ 36) P Value
8.08 (5.72) 8.01 (5.72) 8.25 (5.79)
6 6 6.5
1-32 1-30 2-32
.7484 7.02-9.15 6.71-9.31 6.28-10.21 .5712
6.51 (4.22) 7.58 (4.25) 4.22 (3.13)
5 6 4
1-19 1-19 1-17
5.72-7.30 6.61-8.54 3.16-5.28 <.0001
46 (40.7) 32 (41.6) 14 (38.9) .7878
docetaxel followed by abiraterone acetate and then cabazitaxel; DC ¼ docetaxel followed by
deviation.
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Table 2 Demographic and Clinical Characteristics
Two-Drug Sequence Three-Drug Sequence
Two- vs. Three-Drug
P ValueTotal (N [ 237) DC (n [ 54) DA (n [ 183) Total (N [ 113) DCA (n [ 77) DAC (n [ 36)
Age, years n ¼ 237 n ¼ 54 n ¼ 183 n ¼ 113 n ¼ 77 n ¼ 36
Mean (SD) 72.7 (9.1) 71.2 (9.8) 73.1 (8.9) 68.5 (9.1) 68.1 (9.2) 69.3 (8.7)
Median 73 72.5 73 69 69 68
Range 39-94 39-88 49-94 46-89 46-86 51-89
95% CI 71.5-73.9 68.5-73.9 71.8-74.4 66.8-70.2 66.0-70.2 66.3-72.3 <.0001
CCI, n (%) n ¼ 193 n ¼ 50 n ¼ 143 n ¼ 113 n ¼ 77 n ¼ 36
6 107 (55.4) 29 (58.0) 78 (54.6) 68 (60.2) 50 (64.9) 18 (50.0)
7-8 68 (35.2) 16 (32.0) 52 (36.4) 40 (35.4) 22 (28.6) 18 (50.0)
9-10 17 (8.8) 5 (10.0) 12 (8.4) 3 (2.7) 3 (3.9) 0
11 1 (0.5) 0 1 (0.7) 2 (1.8) 2 (2.6) 0 .1089
Missing 44 4 40 0 0 0
Metastatic Location, n (%) n ¼ 237 n ¼ 54 n ¼ 183 n ¼ 113 n ¼ 77 n ¼ 36
Bone 209 (88.2) 49 (90.7) 160 (87.4) 100 (88.5) 66 (85.7) 34 (94.4)
Liver 19 (8.0) 5 (9.3) 14 (7.7) 13 (11.5) 8 (10.4) 5 (13.9)
Lung 31 (13.1) 6 (11.1) 25 (13.7) 13 (11.5) 11 (14.3) 2 (5.6)
Lymph nodes 69 (29.1) 15 (27.8) 54 (29.5) 40 (35.4) 26 (33.8) 14 (38.9)
Visceral 16 (6.8) 3 (5.6) 13 (7.1) 16 (14.2) 13 (16.9) 3 (8.3)
CNS/not brain 3 (1.3) 0 3 (1.6) 0 0 0
Other 15 (6.3) 4 (7.4) 11 (6.0) 12 (10.6) 9 (11.7) 3 (8.3)
Gleason Score, n (%) n ¼ 166 n ¼ 32 n ¼ 134 n ¼ 86 n ¼ 60 n ¼ 26
6 28 (16.9) 4 (12.5) 24 (17.9) 6 (7.0) 6 (10.0) 0
7 43 (25.9) 11 (34.4) 32 (23.9) 23 (26.7) 16 (26.7) 7 (26.9)
8-10 95 (57.2) 17 (53.1) 78 (58.2) 57 (66.3) 38 (63.3) 19 (73.1) .0296
Missinga 65 21 44 27 17 10
Second-Line Therapy Duration, days n ¼ 113 n ¼ 77 n ¼ 36
Mean (SD) e e e 524.4 (308.8) 555.7 (325.6) 455.3 (260.1)
Median e e e 445 487 394.5
Range e e e 77-1755 77-1755 77-1183
95% CI e e e 466.8-581.9 482.8-630.6 367.3-543.3
Narcotic Use, n (%) 172 (72.6) 40 (74.1) 132 (72.1) 93 (82.3) 66 (85.7) 27 (75.0)
Stage at Diagnosis, n (%) n ¼ 237 n ¼ 54 n ¼ 183 n ¼ 113 n ¼ 76 n ¼ 37
I 3 (1.3) 1 (1.9) 2 (1.1) 0 0 0
II 31 (13.1) 6 (11.1) 25 (13.7) 15 (13.3) 11 (14.5) 4 (10.8)
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Table 2 Continued
Two-Drug Sequence Three-Drug Sequence
Two- vs. Three-Drug
P ValueTotal (N [ 237) DC (n [ 54) DA (n [ 183) Total (N [ 113) DCA (n [ 77) DAC (n [ 36)
III 28 (11.8) 5 (9.3) 23 (12.6) 18 (15.9) 11 (14.5) 7 (18.9)
IV 141 (59.5) 32 (59.3) 109 (59.6) 70 (61.9) 50 (65.8) 20 (54.1)
Unknown 34 (14.3) 10 (18.5) 24 (13.1) 10 (8.8) 4 (5.3) 6 (16.2)
Prostate-Speciﬁc Antigen, ng/mL n ¼ 228 n ¼ 52 n ¼ 176 n ¼ 107 n ¼ 71 n ¼ 36
Mean (SD) 313.4 (818.6) 494.4 (1183.2) 259.9 (669.8) 392.9 (1156.0) 515.1 (1397.1) 152.0 (230.1)
Median 67.1 159.7 57.0 97.1 111.8 76.7
Range 0.09-8250 3.6-8250 0.09-6323 0.80-8755 0.87-8755 0.80-1116
95% CI 206.5-420.2 165.0-823.8b 160.2-359.5b 171.4-614.5 184.4-845.8 74.1-229.8 .1383
Lactate dehydrogenase, U/L n ¼ 72 n ¼ 12 n ¼ 60 n ¼ 32 n ¼ 19 n ¼ 13
Mean (SD) 232.8 (113.6) 243.8 (57.6) 230.6 (121.9) 215.0 (83.2) 204.7 (99.4) 229.9 (51.7)
Median 207 234.5 201 199 180 226
Range 4-718 161-358 4-718 114-502 114-502 176-363
95% CI 206.1-259.4 207.2-280.3 199.1-262.1 185.0-245.0 156.8-252.6b 198.7-261.2b .4725
Alkaline phosphatase, U/L n ¼ 230 n ¼ 51 n ¼ 179 n ¼ 111 n ¼ 76 n ¼ 35
Mean (SD) 177.6 (264.6) 190.6 (250.9) 173.9 (269.0) 196.2 (285.6) 208.8 (326.8) 168.7 (165.0)
Median 102 113 99 100 100 101
Range 3.78-2495 31-1649 3.78-2495 34-2342 34-2342 44-914
95% CI 143.2-212.0 120.0-261.1 134.2-213.6 142.4-249.1 134.1-283.5 112.0-225.4 .7290
Hemoglobin, g/dL n ¼ 229 n ¼ 51 n ¼ 178 n ¼ 111 n ¼ 76 n ¼ 35
Mean (SD) 11.5 (1.8) 11.3 (2.1) 11.5 (1.7) 11.6 (1.8) 11.5 (1.8) 12.0 (1.8)
Median 11.6 11.3 11.6 11.7 11.6 12.0
Range 3.6-19.1 3.6-15.6 8.1-19.1 7.3-17.5 8.1-15.9 7.3-17.5
95% CI 11.2-11.7 10.7-11.9 11.3-11.8 11.3-12.0 11.0-11.9 11.4-12.7 .4638
Abbreviations: CCI ¼ Charlson comorbidity index; CI ¼ conﬁdence interval; CNS ¼ central nervous system; DA ¼ docetaxel followed by abiraterone acetate; DAC ¼ docetaxel followed by abiraterone acetate and then cabazitaxel; DC ¼ docetaxel followed by cabazitaxel; DCA ¼
docetaxel followed by cabazitaxel and then abiraterone acetate; SD ¼ standard deviation.
aUnknown/missing combined for 3-drug cohort.
bP < .05 within cohort.
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314 -similar in all groups of patients (Table 1). In comparing baseline
characteristics between groups and cohorts, parameters were
generally well matched with few exceptions (Table 2). Speciﬁcally,
in the 2-drug cohort, the median PSA level was signiﬁcantly higher
with DC than with DA (159.7 vs. 57.0 ng/mL; P ¼ .0014). In the
3-drug cohort, the median baseline lactate dehydrogenase level was
signiﬁcantly higher in patients receiving DAC compared with those
receiving DCA (226 vs. 180 U/L; P ¼ .0301). Patients receiving all
3 drugs were signiﬁcantly younger (median 69 vs. 73 years;
P < .0001) and had a higher frequency of visceral metastasis
 other site clinical subtype (42.3% vs. 29.4%), whereas the 2-drug
group had a higher frequency of bone  lymph node clinical sub-
type (70.6% vs. 57.7%; P ¼ .0204).
Clinical Outcomes
In the 2-drug cohort, crude estimates indicated a signiﬁcantly
higher median OS for the DA sequence compared with the DC
sequence (17.0 vs. 7.0 months; P ¼ .0002) and a numerically
higher TTF with DA compared with DC, although this did not
reach statistical signiﬁcance (4.0 vs. 3.0 months; P ¼ .7635)
(Table 3). However, when comparing the DC sequence using DA as
reference in a multivariable analysis, adjusted comparisons did not
indicate treatment sequence as a signiﬁcant covariate, suggesting noTable 3 Summary of Effectiveness Outcomes and Multivariable Ana
Outcome
Two-Drug Sequenceb DC (n ¼ 54) DA (n ¼ 183
Median OS,c months (95% CI) 7.0 (5.0-12.0) 17.0 (14.0-N
Median TTF, months (95% CI) 3.0 (2.0-4.0) 4.0 (3.0-5.0
Three-Drug Sequenced DCA (n ¼ 77) DAC (n ¼ 36
Median OS,c months (95% CI) 18.2 (16.0-22.0) 11.8 (9.8-14.
Median TTF1,c months (95% CI) 5.2 (4.3-7.0) 4.3 (2.4-5.1
Median TTF2,c months (95% CI) 10.4 (9.2-12.1) 7.1 (5.6-8.1
Three versus Two-Drug Sequencee Three-Drug (n ¼ 113) Two-Drug (n ¼
Median OS, months (95% CI) 17.0 (14.0-20.0) 17.0 (13.0-N
Abbreviations: AP ¼ alkaline phosphatase; CCI ¼ Charlson comorbidity index; CI ¼ conﬁdence inter
acetate and then cabazitaxel; DC ¼ docetaxel followed by cabazitaxel; DCA ¼ docetaxel followed by
survival; PSA ¼ prostate-speciﬁc antigen; TTF ¼ time to treatment failure; TTF1 ¼ TTF from start of
start of second-line therapy after docetaxel treatment to end of combined second- and third-line th
aOnly signiﬁcant covariates shown.
bTotal covariates included sequence (DC vs. DA), Charlson comorbidity index, bone  lymph node m
(docetaxel) treatment duration, Gleason score, baseline AP level, baseline hemoglobin value, and tre
cP < .01.
dTotal covariates included sequence (DCA vs. DAC, Charlson comorbidity index, bone  lymph node m
age, baseline PSA level, baseline treatment duration, and treatment versus time interaction.
eTotal covariates included drug cohort (3 vs. 2 medications), Charlson comorbidity index, bone  lymp
baseline (docetaxel) treatment duration, baseline AP level, and treatment versus time interaction.
Clinical Genitourinary Cancer August 2015difference in the risk of mortality (P ¼ .1183) or TTF (P ¼ .6480)
between the DA and DC cohorts. Other covariates that appeared to
be associated with OS in this multivariable analysis included
narcotic use (hazard ratio [HR], 2.48; 95% CI, 1.167-5.277),
baseline hemoglobin level (HR, 0.72; 95% CI, 0.593-0.872), and
baseline D treatment duration (HR, 0.95; 95% CI, 0.915-0.987)
(Table 3). The latter result was observed despite the median number
of D cycles not signiﬁcantly differing between groups (DC, 6.5
[range, 2-19] cycles; DA, 6.0 [range, 1-45] cycles; P ¼ .7484)
(Table 3). None of the covariates in the multivariable analysis were
associated with TTF.
In the 3-drug cohort, crude estimates indicated a signiﬁcantly
higher median OS with DCA than with DAC (18.2 vs. 11.8
months; P ¼ .0023) (Figure 2A). In addition, when comparing
the DCA sequence using DAC as the reference in a multivariable
analysis, adjusted comparisons of OS indicated that treatment
sequence was a signiﬁcant covariate, suggesting a lower risk of
mortality in the DCA versus DAC cohorts (P ¼ .0210).
Other covariates—including the CCI (HR, 1.33; 95% CI,
1.060-1.674), duration of second-line therapy (HR, 1.00; 95%
CI, 0.992-0.998), and baseline PSA level per 100 ng/mL
(HR, 1.02; 95% CI, 1.006-1.041)—appeared to be associated
with OS in this multivariable analysis (Table 3). The crudelysis Resultsa
Multivariable Analysis
Signiﬁcant Covariates HR (95% CI) P Value
)
E) Narcotic use 2.48 (1.167-5.277) .0182
Baseline treatment duration 0.95 (0.915-0.987) .0082
Baseline hemoglobin 0.72 (0.593-0.872) .0008
)
)
4) Sequence (DCA vs. DAC) 0.13 (0.022-0.733) .0210
CCI 1.33 (1.060-1.674) .0141
Second-line treatment duration 1.00 (0.992-0.998) .0006
PSA/100 ng/mL 1.02 (1.006-1.041) .0072
) Narcotic use 1.86 (1.012-3.408) .0457
) Sequence (DCA vs. DAC) 0.18 (0.050-0.644) .0084
237)
E) Treatment (3-drug vs. 2-drug) 0.21 (0.092-0.476) .0002
Narcotic use 2.01 (1.240-3.259) .0046
Baseline PSA level 1.01 (1.001-1.027) .0369
Baseline AP level 1.00 (1.000-1.001) .0038
Time on sequence 0.87 (0.806-0.946) .0009
val; DA ¼ docetaxel followed by abiraterone acetate; DAC ¼ docetaxel followed by abiraterone
cabazitaxel and then abiraterone acetate; HR ¼ hazard ratio; NE ¼ not estimated; OS ¼ overall
second-line therapy after docetaxel treatment to end of second-line therapy; TTF2 ¼ TTF from
erapies.
etastasis (vs. visceral/other metastasis), anemia, narcotic use, age, baseline PSA level, baseline
atment versus time interaction.
etastasis (vs. visceral/other metastasis), anemia, narcotic use, duration of second-line therapy,
h node metastasis (vs. visceral/other metastasis), anemia, narcotic use, age, baseline PSA level,
Figure 2 Three-Drug Sequence Results. Unadjusted Kaplan-Meier Plots Show Results for (A) Overall Survival, (B) Time to Treatment
Failure From Start to End of Second-Line Therapy, and (C) Time to Treatment Failure From Second-Line to the End of Third-
Line Therapy
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Table 4 Drug Discontinuation Rates and Reason by Cohort and Sequence
Two-Drug Sequence Three-Drug Sequence
DC
(n [ 54)
DA
(n [ 183)
DCA
(n [ 77)
DAC
(n [ 36)
DCA
(n [ 77)
DAC
(n [ 36)
Drug Discontinued, n (%) C A C A
Death 2 (3.7) 12 (6.6) 0 0 3 (3.9) 1 (2.8)
No response to treatment 0 2 (1.1) 2 (2.6) 0 2 (2.6) 1 (2.8)
Patient choice 2 (3.7) 5 (2.7) 2 (2.6) 2 (5.6) 2 (2.6) 0
Physician choice 3 (5.6) 1 (0.5) 3 (3.9) 0 0 0
Progression or relapse 22 (40.7) 86 (47.0) 43 (55.8) 21 (58.3) 33 (42.9) 26 (72.2)
Toxicity 8 (14.8) 8 (4.4) 7 (9.1) 3 (8.3) 3 (3.9) 1 (2.8)
Other 3 (5.6) 12 (6.6) 2 (2.6) 2 (5.6) 5 (6.5) 2 (5.6)
Treatment completed as scheduled 4 (7.4) 0 6 (7.8) 0 0 1 (2.8)
Insurance/ﬁnance 0 2 (1.1) 0 0 0 0
Unknown/missing 10 (18.5) 55 (30.1) 12 (15.6) 8 (22.2) 29 (37.7) 4 (11.1)
Abbreviations: A ¼ abiraterone acetate; C ¼ cabazitaxel; DA ¼ docetaxel followed by abiraterone acetate; DAC ¼ docetaxel followed by abiraterone acetate and then cabazitaxel; DC ¼ docetaxel
followed by cabazitaxel; DCA ¼ docetaxel followed by cabazitaxel and then abiraterone acetate.
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316 -estimate of median TTF1 was signiﬁcantly greater with DCA
than with DAC (5.2 vs. 4.3 months; P ¼ .0003) (Figure 2B),
although adjusted comparisons in a multivariable analysis did not
identify treatment sequence as a signiﬁcant covariate, suggesting
no difference in TTF1 between the DCA and DAC cohorts.
Narcotic use was the only covariate associated with TTF1
identiﬁed in this multivariable analysis (HR, 1.86; 95% CI,
1.012-3.408; P ¼ .0457). The crude estimate of median TTF2
was also signiﬁcantly greater with DCA than with DAC (10.4 vs.
7.1 months; P ¼ .0002) (Figure 2C), and adjusted comparisons
in a multivariable analysis identiﬁed treatment sequence as a
signiﬁcant covariate, suggesting that the DCA sequence was
associated with a lower risk of TTF2 compared with the DAC
sequence (HR, 0.18; 95% CI, 0.050-0.644; P ¼ .0084).
In comparing outcomes between the 2- and 3-drug groups, crude
estimates for median OS were similar for both groups (both 17.0
months). However, adjusted comparisons in a multivariable analysis
comparing the 3-drug cohort using the 2-drug cohort as reference
identiﬁed the number of treatments administered as a signiﬁcant
covariate, suggesting a lower risk of mortality in the 3-drug group
compared with the 2-drug group (HR, 0.21; 95% CI, 0.092-0.476;
P ¼ .0002). Other covariates associated with mortality in this
multivariable analysis were narcotic use (HR, 2.01; 95% CI,
1.240-3.259; P ¼ .0046), baseline PSA level (HR, 1.01; 95% CI,
1.001-1.027; P ¼ .0369), baseline alkaline phosphatase level
(HR, 1.00; 95% CI, 1.000-1.001; P ¼ .0038), and interaction of
treatment and time (HR, 0.87; 95% CI, 0.806-0.946; P ¼ .0009)
(Table 3).
Treatment Patterns
Drug exposure and discontinuation rates in patients from the
2- and 3-drug cohorts are presented in Table 1. Exposure to C
treatment was signiﬁcantly higher in patients receiving DCA
compared with those receiving DAC (median 6 vs. 4 cycles;
P < .0001). Exposure to A treatment was similar for the DCA and
DAC groups. Reasons for treatment discontinuation were also
evaluated and are presented in Table 4.Clinical Genitourinary Cancer August 2015Discussion
In this retrospective study of 350 patients with mCRPC
receiving C or A, or both, after treatment with D, A was admin-
istered more frequently overall compared with administration of C
(84.6% vs. 47.7%). In the 2-drug group, adjusted comparisons
indicated that treatment with C (n ¼ 54) or A (n ¼ 183) after D
did not signiﬁcantly impact OS outcomes in a multivariable
analysis. Receipt of both C and A (3-drug group) occurred in
32.3% of patients after treatment with D and was independently
associated with an improved OS compared with patients receiving
only C or A (2-drug group [67.7%]) in an adjusted multivariable
analysis (P ¼ .0002). DCA (n ¼ 77) was administered more
frequently than DAC (n ¼ 36) in the 3-drug group. Additionally,
OS and TTF2 were signiﬁcantly greater with DCA compared with
DAC in a multivariable analysis. Improved outcomes with DCA
may be partly attributable to more cycles of C administered in
DCA than in DAC (median 6 vs. 4; P < .0001), whereas the
duration of A treatment was similar for both the DCA and DAC
groups. These data suggest that the sequence of C followed by A
may be more feasible, allowing delivery of more C after D, thereby
resulting in improved survival. Indeed, a modest decrement in
delivery of chemotherapy may compromise survival, as observed in
the MAINSAIL phase III trial (evaluating the safety and effec-
tiveness of lenalidomide in combination with docetaxel and
prednisone for patients with castrate-resistant prostate cancer) in
which a median of 2 fewer cycles of D delivered in the D plus
lenalidomide arm because of toxicities from the combination may
have contributed to lower survival in this arm compared with the
D plus placebo arm.13
The validity of our data is supported by the signiﬁcance of
recognized prognostic factors in the multivariable models, such as
CCI, second-line treatment duration, and baseline PSA levels in the
3-drug group (in addition to speciﬁc sequence) and baseline anemia,
narcotic use (ie, pain), and previous duration of D treatment in the
2-drug group. However, it is difﬁcult to determine the clinical
signiﬁcance of these factors and covariates and whether the results
are clinically meaningful.
Guru Sonpavde et alWe selected a period (April 2011-May 2012) when both C and A
were commercially available. Moreover, we excluded patients
enrolling in clinical trials during the study period, because such
patients are more likely to be a good prognostic group, which may
confound outcomes, as demonstrated in another recent study.14
There were several limitations to the current study, including the
retrospective design and relatively modest sample size. All com-
munity oncology practices are not included in the iKM dataset
because not all US Oncology Network clinics use the full EHR
capabilities of iKM. Furthermore, although data quality checks were
conducted, it is possible that some variables of interest such as
toxicity proﬁles and reasons for treatment discontinuation and
switching of therapy may not be complete. Missing values may
result in exclusion from the study or analysis or imputation of a
value that was captured after treatment. Finally, problems with
inadequate or inaccurate codes in databases may introduce some
level of misclassiﬁcation bias.
Other retrospective studies have suggested that treatment with C
followed by androgen axis inhibitors might lead to improved out-
comes compared with treatment with androgen axis inhibitors fol-
lowed by C.15 Patients whose disease progresses after treatment with
A may have a larger tumor burden and poorer performance status,
precluding the institution or optimal delivery of C. Conversely, pa-
tients whose disease progresses after treatment with C may still be
eligible for treatment with A, given its probable higher tolerability.
Given the rapid proliferation of agents for mCRPC, there exists a
need for tailored therapy. Some potential clinical factors exist. Pa-
tients with a < 16-month response to initial ADT may respond
better to chemotherapy than to subsequent hormonal therapies.11,16
The survival beneﬁt obtained with D or C treatment may be
most pronounced in patients with high Gleason score tumors,17,18
whereas patients with Gleason scores of 8 to 10 have shown
a poor response to A treatment.19 Moreover, the resistance
mechanisms engendered by each line of therapy remain poorly
deﬁned, although all these agents exhibit some element of
cross-resistance.20-22 Although data suggest that targeted androgen
axis inhibitors are effective in the chemotherapy-naive mCRPC
setting, recent data from the CHAARTED study suggest a role for
earlier administration of chemotherapy.11 However, in the absence
of validated predictive biomarkers, consideration should probably
be given to the strategy of administering the most feasible
sequence of agents.
Conclusion
Based on the ﬁndings of this retrospective analysis, exposure to all
3 agents in the DCA sequence may be a more optimal sequence of
treatment for mCRPC than the DAC sequence. However, these
results are exploratory, and prospective validation in a randomized
trial or prospective observational study, or both, is necessary.
Clinical Practice Points
 First-line treatment with D for mCRPC yields a median OS of
nearly 19 months. Recent years have seen a marked expansion in
available treatment options for mCRPC.
 C, A, and enzalutamide all improve OS when administered after
D treatment. However, in the absence of prospective trials
comparing sequences of agents administered after treatment withD, the optimal sequence is unknown, and there is no clear evi-
dence to support clinical decisions.
 McKesson Specialty Health’s iKM EHR allows analysis and
comparison of different treatment sequences in patients with
mCRPC. In the current retrospective study of 350 patients with
mCRPC receiving C or A, or both, after D treatment, adjusted
comparisons in a multivariable analysis suggested that clinical
outcomes for D followed by A only were not signiﬁcantly
improved compared with D followed by C only.
 In a multivariable analysis, administration of both C and A after
treatment with D was associated with improved OS compared
with administration of only C or A after treatment with D. For
the 3-drug regimens, OS and TTF were signiﬁcantly greater with
the DCA sequence compared with DAC in the multivariable
analysis.
 Given the rapid growth of agents for mCRPC, there is a need for
tailored therapy. Without predictive biomarkers, consideration
should be given to the strategy of administering the most feasible
sequence of agents.
 Based on this retrospective analysis, DCA may be a more optimal
treatment sequence for mCRPC compared with DAC. These
results are exploratory and require prospective validation.Acknowledgments
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